Kisspeptin-10

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Kisspeptin-10

Upstream regulator of GnRH release, studied in reproductive endocrinology.

Evidence category: Clinical study. This describes the source category, not approval or certainty.

Regulatory statement in source: Not FDA-approved.

Kisspeptin sits upstream of the reproductive hormone axis and has been studied in real academic trials, more than most research peptides. The linked human work uses kisspeptin-54 as a trigger for egg maturation in IVF: a phase 2 trial in 60 women at high risk of ovarian hyperstimulation, and a phase 2 randomised trial in 62 women. A further clinical study looked at its effects on ovarian granulosa cells. The wiki also records brain imaging studies reporting effects on sexual and romantic brain processing in men. It is not approved for any indication.

Benefits reported in the imported source

• Studied in real academic phase 2 trials, more than most research peptides
• As an IVF trigger, kisspeptin-54 matured eggs in most women with no moderate or severe hyperstimulation
• A second dose raised egg yield without more ovarian over-response

Risks and limits

• The human trials used kisspeptin-54 in IVF, not this form for other purposes
• Brain imaging findings on sexual processing come from the wiki, not from outcome trials

Source bottom line: Kisspeptin has genuine phase 2 IVF trial data under a related form, but is approved for nothing.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 0.3–0.7 hours. Human infusion studies Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Peptide Wiki: Kisspeptin-10 (wiki-origin reference; not independent corroboration)
• Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy (Abbara et al. 2015)
• A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial (Abbara et al. 2017)
• The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function (Owens et al. 2018)
• PubMed: kisspeptin-10